Poppe Tanya, Thompson Benjamin, Boardman James P, Bastin Mark E, Alsweiler Jane, Deib Gerard, Harding Jane E, Crowther Caroline A
Department of Optometry and Vision Science, University of Auckland, Auckland, New Zealand; Centre for the Developing Brain, Department of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
Department of Optometry and Vision Science, University of Auckland, Auckland, New Zealand; School of Optometry and Vision Science, University of Waterloo, Waterloo, Canada.
EBioMedicine. 2022 Apr;78:103923. doi: 10.1016/j.ebiom.2022.103923. Epub 2022 Mar 21.
Magnesium sulphate given to women prior to very preterm birth protects the perinatal brain, so fewer babies die or develop cerebral palsy. How magnesium sulphate exerts these beneficial effects remains uncertain. The MagNUM Study aimed to assess the effect of exposure to antenatal magnesium sulphate on MRI measures of brain white matter microstructure at term equivalent age.
Nested cohort study within the Magnesium sulphate at 30 to <34 weeks' Gestational age Neuroprotection Trial (MAGENTA). Australian New Zealand Clinical Trials Registry ACTRN12611000491965. Mothers at risk of preterm birth at 30 to <34 weeks' gestation were randomised to receive either 4 g of magnesium sulphate heptahydrate [8 mmol magnesium ions], or saline placebo, when preterm birth was planned or expected within 24 h. Participating babies underwent diffusion tensor MRI at term equivalent age. The main outcomes were fractional anisotropy across the white matter tract skeleton compared using Tract-based Spatial Statistics (TBSS), with adjustment for postmenstrual age at birth and at MRI, and MRI site. Researchers and families were blind to treatment group allocation during data collection and analyses.
Of the 109 babies the demographics of the 49 babies exposed to magnesium sulphate were similar to the 60 babies exposed to placebo. In babies whose mothers were allocated to magnesium sulphate, fractional anisotropy was lower within the corticospinal tracts and corona radiata, the superior and inferior longitudinal fasciculi, and the inferior fronto-occipital fasciculi compared to babies whose mothers were allocated placebo (P < 0·05).
In babies born preterm after 30 weeks' gestation, antenatal magnesium sulphate exposure did not promote development of white matter microstructure in pathways affecting motor or cognitive function. This suggests that if the neuroprotective effect of magnesium sulphate treatment prior to preterm birth is confirmed at this gestation, the mechanisms are not related to accelerated white matter maturation inferred from fractional anisotropy.
This study was funded by a project grant from the Health Research Council of New Zealand (HRC 14/153).
在极早产之前给孕妇使用硫酸镁可保护围产期大脑,从而减少婴儿死亡或患脑瘫的几率。硫酸镁如何发挥这些有益作用尚不确定。镁神经保护效用研究(MagNUM Study)旨在评估产前暴露于硫酸镁对足月等效年龄时脑白质微观结构MRI测量值的影响。
在孕30至<34周硫酸镁神经保护试验(MAGENTA)中进行嵌套队列研究。澳大利亚新西兰临床试验注册中心编号ACTRN12611000491965。孕30至<34周有早产风险的母亲,在计划或预计在24小时内早产时,被随机分配接受4克七水硫酸镁[8毫摩尔镁离子]或生理盐水安慰剂。参与研究的婴儿在足月等效年龄时接受扩散张量MRI检查。主要结局是使用基于纤维束的空间统计学(TBSS)比较白质束骨架上的各向异性分数,并对出生时和MRI检查时的孕龄以及MRI检查部位进行校正。在数据收集和分析过程中,研究人员和家庭对治疗组分配情况不知情。
在109名婴儿中,49名暴露于硫酸镁的婴儿的人口统计学特征与60名暴露于安慰剂的婴儿相似。与母亲被分配接受安慰剂的婴儿相比,母亲被分配接受硫酸镁的婴儿,其皮质脊髓束、放射冠、上纵束和下纵束以及额枕下束内的各向异性分数较低(P<0.05)。
在孕30周后早产的婴儿中,产前暴露于硫酸镁并未促进影响运动或认知功能的通路中白质微观结构的发育。这表明,如果在此孕周证实早产前硫酸镁治疗具有神经保护作用,其机制与从各向异性分数推断出的白质加速成熟无关。
本研究由新西兰健康研究委员会的一项项目资助(HRC 14/153)。